LexaGene’s MiQLab provides rapid plague detection for
BEVERLY, Mass., June 17, 2021 (GLOBE NEWSWIRE) – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG), a molecular diagnostics company, is pleased to announce that today the Dr. Jack Regan, CEO and Founder of LexaGene, will present at the Threat and Pathogen Detection conference the ability of the MiQLab ™ system to detect the pathogen responsible for plague.
Dr Jack Regan says: “Our MiQLab system is both open access and designed for point-of-care use, making it a Ffirst–of–his–kind system. These unique characteristics are essential for early point-of-care diagnostics, improving the likelihood of successful biocontainment of new pathogens. The past 18 months have highlighted how much humanity needs advanced technologies like MiQLab to better contain a new pathogen capable of causing a pandemic. MiQLab is uniquely suited to fill the massive technology gap in our testing infrastructure as it has the potential to dramatically reduce the response time from the initial identification of a new pathogen to the rapid deployment of new detection tests at the point of care. . Minimizing this response time dramatically improves the chances of successful containment of pathogens so that countless lives can be saved. “
A brief interview with Dr. Regan regarding LexaGene’s value proposition for pandemic prevention can be viewed HERE.
The 28e International Biothreat and Pathogen Detection Conference is an internationally recognized meeting for experts in the detection and identification of biological threats. This conference addresses key topics in pathogen detection and presents the latest technological and R&D innovations in rapid pathogen identification. In addition, this meeting focuses on the latest strategies to overcome obstacles surrounding the rapid identification of global biological threats and the introduction of new laboratory technologies in the field.
History is replete with numerous cases of natural epidemics of biological threat agents that have collectively killed hundreds of millions of people. Plague is arguably the deadliest pathogen of all time. Other pathogens also caused massive loss of life, including the 1918 influenza pandemic, HIV, Ebola,1 and SARS-CoV-2. Unfortunately, the intentional use of biomenace agents has been documented from the Middle Ages until the two world wars and even into modern times.2 Most recent examples include the 1984 Salmonella bioterrorist attack in Oregon3 and the 2001 anthrax letters.4
The plague has caused many pandemics in human history.5 Due to its history as a killer and the possibility that the plague will still cause a large number of deaths and the difficulty of successful containment, it is classified by the government as a Category A bioterrorism agent.6
In order to demonstrate the capabilities of MiQLab for the detection of biomenace agents, LexaGene developed a plague test and performed an analytical evaluation with artificial samples.
Dr Regan comments: “I am extremely satisfied with the quality of our plague test. In silico analysis showed close to 100% coverage of all plague genomes. Analytical studies have shown that our test correlated extremely closely with quantitative culture (R2 > 0.94). Our test is also very sensitive, as we were able to reliably detect levels 1000 times lower than the levels of this bacterium commonly detected in the blood of infected patients.7 Finally, in an exclusive study, our test was not cross-reacted with any of the phylogenetically related microorganisms tested. These high-quality test results demonstrate MiQLab’s capabilities as a monitoring and detection tool in the face of a natural or intentional biological threat.
To learn more about LexaGene and the MiQLab system or to subscribe to company updates, visit www.lexagene.com or follow us on Twitter or LinkedIn.
On behalf of the board of directors
Dr Jack Regan
Managing Director & Chairman
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostic company that develops molecular diagnostic systems for the detection of pathogens and genetic testing for other molecular markers for rapid on-site testing in veterinary diagnostics, food safety and for use on open access markets such as clinical research, agricultural testing and biodefense. End users simply need to take a sample, load it onto the instrument with a sample preparation cartridge, enter the sample ID and press “Go”. The MiQLab ™ System offers excellent sensitivity, specificity and detection range and can return results in approximately two hours. The unique open access feature is designed for custom testing so end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors – including availability of funds, results of fundraising efforts, success of technology development efforts, cost of purchasing critical parts, instrument performance, market acceptance of the technology , regulatory acceptance and licensing issues – which could cause actual results to differ materially from the Company’s expectations, as disclosed in Company documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.
 Walper SA, et al. Detection of biomenace agents: from current diagnostics to the development of sensor technologies. ACS Sens. 2018; 3: 1894-2024.
 Riedel, S. Biological warfare and bioterrorism: a historical review. BUMC Proc. 2004, 17, 400-406.
 Montminy, S., Khan, N., McGrath, S. et al. Yersinia pestis virulence factors are overcome by a strong lipopolysaccharide response. Nat Immunol 7, 1066-1073 (2006). https://doi.org/10.1038/ni1386